title: [Molecular targeted therapy in colorectal cancer].
abstract: BACKGROUND
  A diversity of cytotoxic and molecularly targeting agents are now offered for colorectal cancer; 5-fluorouracil was until recently the only available therapy. Molecular targeting agents inhibit cellular signalling mechanisms that govern tumour cell proliferation and survival.
  
  
  METHODS
  The article is mainly based on publications identified by searching PubMed, as well as abstracts and presentations at recent international congresses.
  
  
  CONCLUSIONS
  Receptor tyrosine kinases are involved in cellular processes such as proliferation and angiogenesis, and signalling activities evoked by these enzymes are targets for pharmacological inhibition. The antibody bevacizumab inhibits angiogenesis. Randomized studies have shown that survival or time to progression of metastatic disease is improved when bevacizumab is combined with cytotoxic drugs (5-fluorouracil with or without irinotecan or oxaliplatin). The antibody cetuximab inhibits activation of a tumour cell growth factor receptor, and was approved for therapy on the basis of a large randomized phase 2 study. A wide array of small-molecular inhibitors of signalling by receptor tyrosine kinases are under clinical investigation, but their therapeutic contribution in metastatic colorectal cancer needs to be clarified. According to Nordic recommendations on the use of molecular targeted agents in combination with chemotherapy for metastatic colorectal cancer, bevacizumab should be considered in the first-line treatment of patients with a good performance status and cetuximab in third-line treatment.
authors.affiliation: Akershus universitetssykehus, Universitetet i Oslo og Tumorbiologisk avdeling, Rikshospitalet, 0310 Oslo. a.h.ree@medisin.uio.no
authors.forename: Anne Hansen
authors.initials: AH
authors.lastname: Ree
authors.forename: Ase
authors.initials: A
authors.lastname: Bratland
authors.forename: Svein
authors.initials: S
authors.lastname: Dueland
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D054697:Cytostatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000187:drug effects; D006801:Humans; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000187:drug effects; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D054697:Cytostatic Agents; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor